Side-by-side · Research reference

CrystagenvsDSIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED12/40 cited

BHuman-MechanisticAUTO-DRAFTED8/36 cited

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

01Mechanism of Action

Parameter

Crystagen

DSIP

Primary target

B-lymphocytes in splenic tissueСhervyakova 2014

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pathway

B-cell activation → Immune modulation during agingСhervyakova 2014

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

Downstream effect

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Feedback intact?

Unknown — bioregulator mechanism not fully characterized

—

Origin

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Antibody development

—

02Dosage Protocols

Parameter

Crystagen

DSIP

Standard dose

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

100–200 mcg SQ pre-sleepSchneider 1986

Evidence basis

Animal / mechanistic

Human-mechanistic + early clinicalSchneider 1986

Route

Subcutaneous (presumed from bioregulator class)

—

Frequency

Unknown — bioregulator protocols variable

Once daily, pre-sleep

Duration

Unknown — chronic administration presumed in animal models

8–12 weeks per cycle

Half-life

Not reported

Short plasma; CNS effects last hours

Lower / starter dose

—

50 mcg pre-sleep

Reconstitution

—

Bacteriostatic water

Timing

—

30–60 min pre-sleep

04Side Effects & Safety

Parameter

Crystagen

DSIP

Published adverse events

None reported in available animal literature

—

Human safety data

Absent — no controlled human trials identified

—

Autoimmune considerations

Theoretical concern with B-cell modulators in predisposed individuals

—

Injection site reaction

—

Mild irritation

Drowsiness

—

Expected effect (intentional)

Vivid dreams

—

Anecdotally reported

Long-term safety

—

Limited modern RCT data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Crystagen

·Active autoimmune disease (theoretical)

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Relative Contraindications

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

05Administration Protocol

Parameter

Crystagen

DSIP

1. Route

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

Add 1–2 mL bacteriostatic water to vial.

2. Reconstitution

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

SQ — abdomen. Rotate sites.

3. Timing

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

30–60 min pre-sleep.

4. Storage

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G insulin syringe.

06Stack Synergy

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014

DSIP

— no documented stacks